explore -WSS

explore

author：focus 2025-09-06 03:32:55 - browse：182

Three boxes of Wegovy stands in a line — coverage from STAT — Steffen Trumpf/picture alliance/Getty Images

WASHINGTON — Novo Nordisk’s newly won permission to market the heart benefits of its obesity drug Wegovy could provide a backdoor way to expand access to the drug for people on Medicare, experts told STAT.

Currently, Medicare is prohibited by law from covering medications for obesity treatment alone. While companies that manufacture wildly popular anti-obesity medications and their allies haven’t been successful in lobbying Congress to change the law, the Food and Drug Administration’s move could give doctors an avenue to prescribe the medications to some Medicare patients.

Wegovy’s new label indicates that the drug can be used to reduce the risk of major heart complications for people who are overweight or obese and have existing heart disease, Novo said in a statement Friday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Wegovy’s successful heart trial raises vital question about weight loss

WSS

Ambulance rides for just $100? Advisers want major billing fixes

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

Abortion clinic in Cancun will cater to Americans

The new shift in health care is toward less care

NIH trials fail to test meaningful long Covid therapies, experts say

Excited delirium, Elijah McClain, and emergency physicians

leisure time

explore

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Abortion clinic in Cancun will cater to Americans

As demand for Covid shots wanes, Moderna seeks its next success

Removing probiotics from the NICU could threaten preemies' health

State Dept. review finds Biden bears some blame for Afghanistan failures

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

Walensky prepares to leave CDC — and Congress — behind

Study: New antibiotic targets gonorrhea as well as last existing drug

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Ambulance rides for just $100? Advisers want major billing fixes

hotspot

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Friends ask where James Watson's attitudes about race came from

Victims of gun violence feel impacts long after bullet wound

How to use technology to prevent future drug shortages

Study: New antibiotic targets gonorrhea as well as last existing drug

Anavex keeps shifting the goalposts in its clinical trials

hotspot

focus

knowledge

focus